St. Jude, CardioMEMS, CHAMPION trial, heart failure, reduced ejection fraction

Heart failure patients with reduced ejection fraction experienced significant HF mortality and hospitalization reductions via guideline-directed medical therapy managed by pulmonary artery pressure monitoring with the CardioMEMS HF System, according to a data analysis from the CHAMPION trial.
Minneapolis Heart Institute Foundation, PCI, STEMI, late presenters

New research from the Minneapolis Heart Institute Foundation (MHIF) finds that percutaneous coronary intervention for heart attacks can still be beneficial for patients who get to their more than 12 hours after their chest pain has started. Timothy Henry, M.D., lead MHIF researcher and director of cardiology at Cedars-Sinai Medical Center in Los Angeles, presented the study results at the 2015 American College of Cardiology (ACC) conference in San Diego.
Computed tomography, coronary CT angiography, PROMISE trial, ACC

Results from the PROMISE clinical trial confirmed what many cardiologists and radiologists have long suspected to be true: Coronary computed tomographic angiography (coronary CTA) is extraordinarily effective in accurately diagnosing patients with low to moderate chest pain.
Medtronic, Drug Filled Stent, clinical trial, ACC

Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed controlled and efficacious drug elution into the arterial wall without a polymer carrier, while reducing diameter stenosis and achieving complete stent coverage quickly without inflammation. Based on these results, Medtronic plans to initiate a clinical trial in the coming months.

Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman left atrial appendage closure device. The Watchman device offers a new stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation who are seeking an alternative to long-term warfarin therapy.

Toshiba America Medical Systems Inc.’s Infinix 4DCT provides clinicians with faster, safer and more accurate interventions. Combining interventional radiology (IR) and computed tomography (CT), healthcare providers can plan, treat and verify in a single clinical setting for better patient care – rather than transferring patients between departments, risking infection and dragging out procedure times.

Precision Image Analysis (PIA) will be showcasing their remote post-processing solution for cardiac magnetic resonance (CMR) and cardiac computed tomography (CT) at the 2015 American College of Cardiology scientific session.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now